CPT® Code 90684

Pneumococcal bacteria are a significant cause of serious infections, including pneumococcal pneumonia, bacteremia, and meningitis. The pneumococcal conjugate vaccine, specifically the 21 valent formulation (PCV21), is designed to provide immunity against these bacteria. This vaccine is created using a purified component of the bacteria's cell wall, which is then combined with a nontoxic variant of diphtheria known as CRM197. This combination enhances the immune response to the vaccine. The PCV21 vaccine is differentiated from other pneumococcal vaccines by the number of serotypes of Streptococcus pneumoniae it covers. In contrast to the 20 valent pneumococcal conjugate vaccine (PCV20), which covers specific serotypes, the PCV21 vaccine offers protection against an expanded range of serotypes, including 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B. This broader coverage is particularly important for adults aged 18 and older, as it helps protect against the main serotypes responsible for invasive pneumococcal disease and pneumonia. The administration of this vaccine is performed via intramuscular injection, which is a separate procedure that is reported independently.